Co-Authors
This is a "connection" page, showing publications co-authored by ANNE TSAO and JACK A ROTH.
Connection Strength
1.153
-
Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer. 2009 Jan; 10(1):36-41.
Score: 0.346
-
Surgery: Future directions in multimodality therapy for NSCLC. Nat Rev Clin Oncol. 2010 Jan; 7(1):10-2.
Score: 0.093
-
Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90.
Score: 0.088
-
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):231-9.
Score: 0.071
-
Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations. Front Oncol. 2023; 13:1216999.
Score: 0.060
-
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
Score: 0.054
-
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).
Score: 0.052
-
Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2022 01; 113(1):200-208.
Score: 0.051
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.050
-
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
Score: 0.048
-
Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
Score: 0.047
-
Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. J Thorac Dis. 2019 Apr; 11(4):1269-1278.
Score: 0.044
-
Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018 05 01; 53(5):960-966.
Score: 0.041
-
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3354-3362.
Score: 0.039
-
The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
Score: 0.028
-
Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009 Oct 24; 8:91.
Score: 0.023
-
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov; 84(5):1685-92; discussion 1692-3.
Score: 0.020